What are the key takeaways from this Biotech Hangout episode?

Key insights include: **FDA Leadership Disconnect:** When a new agency head like Vinay Prasad takes over CBER, prior agreements with review teams carry no binding obligation. Companies spanning two leadership regimes face the highest risk of surprise CRLs, as clinical deficiencies can emerge after manufacturing-only rejections with no prior warning from reviewer interactions.; **Regulatory Signal vs. Action:** Track what the FDA does, not what it says. Despite public messaging favoring rare disease acceleration and regulatory flexibility, industry is experiencing greater stringency. Prasad's twenty-year publication and video record signals a stringent regulatory philosophy that predates his FDA role and should be weighted heavily over official press statements.; **CAR-T Acquisition Timing:** Gilead's acquisition of Arcellix followed BLA acceptance for anito-cel, a BCMA CAR-T with a cleaner safety profile than carvykti. Deals structured around existing revenue-sharing agreements primarily shift the P&L middle rather than top-line economics, making BLA acceptance the key catalyst to watch before similar partnership-to-acquisition transitions occur.

What did Adam Furstein discuss on Biotech Hangout?

Biotech Hangout Episode 174 examines the widening gap between FDA rhetoric on rare disease flexibility and actual agency decisions, covering Atara/Pierre Fabre's double CRL, Gilead's Arcellix acquisition, Novo Nordisk's cagrilintide failure against tirzepatide, and Xenon's upcoming phase three epilepsy readout with Adam Feuerstein. Key topics include: **FDA Leadership Disconnect:** When a new agency head like Vinay Prasad takes over CBER, prior agreements with review teams carry no binding obligation. Companies spanning two leadership regimes face the highest risk of surprise CRLs, as clinical deficiencies can emerge after manufacturing-only rejections with no prior warning from reviewer interactions.; **Regulatory Signal vs. Action:** Track what the FDA does, not what it says. Despite public messaging favoring rare disease acceleration and regulatory flexibility, industry is experiencing greater stringency. Prasad's twenty-year publication and video record signals a stringent regulatory philosophy that predates his FDA role and should be weighted heavily over official press statements..

How long is this episode of Biotech Hangout?

This episode is 57 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Biotech Hangout

Episode 174 - February 27, 2026

February 27, 2026

57 min episode · 2 min read

Adam Furstein

Episode

57 min

Read time

2 min

Topics

Relationships, Fundraising & VC, Leadership

AI-Generated Summary

Published Mar 1, 2026

Key Takeaways

✓FDA Leadership Disconnect: When a new agency head like Vinay Prasad takes over CBER, prior agreements with review teams carry no binding obligation. Companies spanning two leadership regimes face the highest risk of surprise CRLs, as clinical deficiencies can emerge after manufacturing-only rejections with no prior warning from reviewer interactions.
✓Regulatory Signal vs. Action: Track what the FDA does, not what it says. Despite public messaging favoring rare disease acceleration and regulatory flexibility, industry is experiencing greater stringency. Prasad's twenty-year publication and video record signals a stringent regulatory philosophy that predates his FDA role and should be weighted heavily over official press statements.
✓CAR-T Acquisition Timing: Gilead's acquisition of Arcellix followed BLA acceptance for anito-cel, a BCMA CAR-T with a cleaner safety profile than carvykti. Deals structured around existing revenue-sharing agreements primarily shift the P&L middle rather than top-line economics, making BLA acceptance the key catalyst to watch before similar partnership-to-acquisition transitions occur.
✓GLP-1 Competitive Benchmarking: Cagrilintide failed non-inferiority against tirzepatide at week 84, posting roughly 23% weight loss versus 25.5% for tirzepatide, with worse tolerability signals. Novo's simultaneous 50% list price cut on Wegovy and Ozempic largely mirrors IRA-negotiated Medicare pricing, functioning as gross-to-net normalization rather than a genuine competitive pricing move.
✓Phase Three Endpoint Design: For Xenon's focal onset seizure trial X-TOLL 2, the primary endpoint is measured at twelve weeks versus eight weeks in the phase two X-TOLL study. Because anti-seizure medications show progressive efficacy gains through weeks nine through twelve, the longer averaging window dilutes early low-response weeks, potentially offsetting the typical phase two-to-three effect size decline.

What It Covers

Biotech Hangout Episode 174 examines the widening gap between FDA rhetoric on rare disease flexibility and actual agency decisions, covering Atara/Pierre Fabre's double CRL, Gilead's Arcellix acquisition, Novo Nordisk's cagrilintide failure against tirzepatide, and Xenon's upcoming phase three epilepsy readout with Adam Feuerstein.

Key Questions Answered

•FDA Leadership Disconnect: When a new agency head like Vinay Prasad takes over CBER, prior agreements with review teams carry no binding obligation. Companies spanning two leadership regimes face the highest risk of surprise CRLs, as clinical deficiencies can emerge after manufacturing-only rejections with no prior warning from reviewer interactions.
•Regulatory Signal vs. Action: Track what the FDA does, not what it says. Despite public messaging favoring rare disease acceleration and regulatory flexibility, industry is experiencing greater stringency. Prasad's twenty-year publication and video record signals a stringent regulatory philosophy that predates his FDA role and should be weighted heavily over official press statements.
•CAR-T Acquisition Timing: Gilead's acquisition of Arcellix followed BLA acceptance for anito-cel, a BCMA CAR-T with a cleaner safety profile than carvykti. Deals structured around existing revenue-sharing agreements primarily shift the P&L middle rather than top-line economics, making BLA acceptance the key catalyst to watch before similar partnership-to-acquisition transitions occur.
•GLP-1 Competitive Benchmarking: Cagrilintide failed non-inferiority against tirzepatide at week 84, posting roughly 23% weight loss versus 25.5% for tirzepatide, with worse tolerability signals. Novo's simultaneous 50% list price cut on Wegovy and Ozempic largely mirrors IRA-negotiated Medicare pricing, functioning as gross-to-net normalization rather than a genuine competitive pricing move.
•Phase Three Endpoint Design: For Xenon's focal onset seizure trial X-TOLL 2, the primary endpoint is measured at twelve weeks versus eight weeks in the phase two X-TOLL study. Because anti-seizure medications show progressive efficacy gains through weeks nine through twelve, the longer averaging window dilutes early low-response weeks, potentially offsetting the typical phase two-to-three effect size decline.

Notable Moment

The panel noted a striking political irony: the Trump administration, whose base holds libertarian views favoring lower drug approval hurdles and physician-patient autonomy, is now drawing criticism from MAGA-aligned publications like the New York Post for FDA decisions that are functionally more restrictive than the prior administration's approach.

Know someone who'd find this useful?

Episode Transcript

You're listening to Bio Tech Hangout, a live and unedited weekly discussion of all the latest news in our industry. And, we're here with a group of biotech leaders and experts. I'm Tess Cameron, and my cohost today are Josh Shimmer, Brian Skorney, and we are, very pleased to have a special guest with us today, Adam Furstein. So thank you so much for joining us, Adam. For more information about our hosts and guest speakers or to listen to the most recent episode, please go to biotechhangout.com. So, I don't know about, everyone else, but I feel like we need a new segment for Bio Tech Hangout, which is, FDA update: good or bad for biomedical innovation? And this week was very much about, updates from the FDA and how to interpret various decisions. You know, I think everyone will remember we ended last week, with the New England Journal of Medical, New New England Journal of Medicine article by McCarrie and Prasad in which they laid out a new standard, for one trial approval, really ending what they called, the two trial dogma. And, you know, I think that article really spoke to their thinking on regulatory flexibility and trying to enable innovation. Then at the, you know, very end of last week, we wrapped up Friday with a CRL for DISC medicines and their drug, Bidapertin. And this is a drug for erythropoietic, protoporphia, which is a genetic condition where sun exposure, can lead to severe burning, itching, swelling. These are patients who have to spend a lot of time inside and, this this drug, Bidapertin, was was, you know, had actually previously received a voucher from the commissioner's, you know, national priority review voucher which was, you know, kind of an exemplifier of this, you know, approach for, you know, regulatory flexibility and, you know, and speed. So, you know, I think that kind of set the stage for then what we saw this week, which was a flurry of editorials and other news and, you know, further commentary on, you know, the FDA's, you know, the FDA's, you know, position and, of, you know, position and approach towards really setting the standards for what a drug needs to see for approval with, you know, a real focus on, rare disease. So why don't we get started there? And, Adam, why don't we why don't we start with you and, Atera and, Pierre Fabry and, the rejection that that they saw from the FDA? Yeah. I I think, you know, the story that I wrote this week, again, about about a drug called Evalu. It's a cell therapy for this very a very rare form of cancer that arises in people who undergo stem cell transplants or organ transplants. You know, and I think the story kinda really speaks to some of the tension that we're seeing tests out there, which is, you know, kind of trying to, understand and and listen to what the FDA …

Get the full transcript (10,064 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Biotech Hangout transcripts →